 Nuclear Proteins
"Nuclear Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
| Descriptor ID |
D009687
|
| MeSH Number(s) |
D12.776.660
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nuclear Proteins".
Below are MeSH descriptors whose meaning is more specific than "Nuclear Proteins".
This graph shows the total number of publications written about "Nuclear Proteins" by people in this website by year, and whether "Nuclear Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 1 | 2 | 3 | | 1997 | 7 | 2 | 9 | | 1998 | 7 | 4 | 11 | | 1999 | 7 | 5 | 12 | | 2000 | 11 | 5 | 16 | | 2001 | 13 | 4 | 17 | | 2002 | 12 | 4 | 16 | | 2003 | 11 | 10 | 21 | | 2004 | 6 | 9 | 15 | | 2005 | 7 | 8 | 15 | | 2006 | 6 | 11 | 17 | | 2007 | 7 | 7 | 14 | | 2008 | 9 | 8 | 17 | | 2009 | 10 | 7 | 17 | | 2010 | 8 | 5 | 13 | | 2011 | 12 | 8 | 20 | | 2012 | 9 | 8 | 17 | | 2013 | 16 | 8 | 24 | | 2014 | 23 | 10 | 33 | | 2015 | 16 | 13 | 29 | | 2016 | 18 | 7 | 25 | | 2017 | 13 | 11 | 24 | | 2018 | 7 | 11 | 18 | | 2019 | 6 | 6 | 12 | | 2020 | 7 | 6 | 13 | | 2021 | 9 | 5 | 14 | | 2022 | 3 | 11 | 14 | | 2023 | 1 | 6 | 7 | | 2024 | 8 | 10 | 18 | | 2025 | 6 | 0 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Nuclear Proteins" by people in Profiles.
-
Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, ?ucenka A, de Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, K?hn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, D?hner H, Greco C, Kovacsovics T, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly JS. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025 Aug 28; 146(9):1065-1077.
-
Chan YS, Gao Q, Robinson SA, Wang W, Filandrova R, Weinhold LM, Cabrera ML, Zhang M, Ambati CSR, Lerario AM, Putluri N, Kiseljak-Vassiliades K, Wierman ME, Habra MA, Hammer GD, Veverka V, Cermakova K, Hodges HC. ß-catenin functions as a molecular adapter for disordered cBAF interactions. Mol Cell. 2025 Aug 21; 85(16):3041-3056.e9.
-
Guo XS, Khalifa A, Selvam K, Kutateladze TG, Liu WR. Development of Chemical Tools for the Human YEATS Domain. ACS Chem Biol. 2025 Aug 15; 20(8):1828-1840.
-
Erickson B, Fedoryshchak R, Fong N, Sheridan R, Larson KY, Saviola AJ, Mouilleron S, Hansen KC, Treisman R, Bentley DL. PP1/PNUTS phosphatase binds the restrictor complex and stimulates RNA Pol II transcription termination. Cell Rep. 2025 May 27; 44(5):115564.
-
Oguh AU, Haemmerle MW, Sen S, Rozo AV, Shrestha S, Cartailler JP, Fazelinia H, Ding H, Preza S, Yang J, Yang X, Sussel L, Alvarez-Dominguez JR, Doliba N, Spruce LA, Arrojo E Drigo R, Stoffers DA. E3 ligase substrate adaptor SPOP fine-tunes the UPR of pancreatic ? cells. Genes Dev. 2025 Feb 03; 39(3-4):261-279.
-
Becht DC, Selvam K, Lachance C, C?t? V, Li K, Nguyen MC, Pareek A, Shi X, Wen H, Blanco MA, C?t? J, Kutateladze TG. A multivalent engagement of ENL with MOZ. Nat Struct Mol Biol. 2025 Apr; 32(4):709-718.
-
Frisch A, Ganzel C, Ofran Y, Krayem B, Haran A, Vainstein V, Aumann S, Even-Zohar NG, Nachmias B. Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission. Eur J Haematol. 2025 Apr; 114(4):641-649.
-
Schuetze KB, Stratton MS, Bagchi RA, Hobby ARH, Felisbino MB, Rubino M, Toni LS, Reges C, Cavasin MA, McMahan RH, Alexanian M, Vagnozzi RJ, McKinsey TA. BRD4 inhibition rewires cardiac macrophages toward a protective phenotype marked by low MHC class II expression. Am J Physiol Heart Circ Physiol. 2025 Feb 01; 328(2):H294-H309.
-
Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. J Thorac Oncol. 2025 Mar; 20(3):383-394.
-
Alexanian M, Padmanabhan A, Nishino T, Travers JG, Ye L, Pelonero A, Lee CY, Sadagopan N, Huang Y, Auclair K, Zhu A, An Y, Ekstrand CA, Martinez C, Teran BG, Flanigan WR, Kim CK, Lumbao-Conradson K, Gardner Z, Li L, Costa MW, Jain R, Charo I, Combes AJ, Haldar SM, Pollard KS, Vagnozzi RJ, McKinsey TA, Przytycki PF, Srivastava D. Chromatin remodelling drives immune cell-fibroblast communication in heart failure. Nature. 2024 Nov; 635(8038):434-443.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|